Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capivasertib plus docetaxel versus placebo plus docetaxel in metastatic castration-resistant prostate cancer
NL-OMON59863Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Capivasertib + docetaxel with Placebo + docetaxel (2 arms). Primary endpoints: Overall survival and Radiographic progression-free survival. Started Apr 2023; status: completed.
02
Drugs
capivasertib
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NL-OMON59863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59863.